Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -6 of 6
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
12/1/1998
1.
Phase I/II Pilot Study of Bispecific Antibody 520C9xH22 with GM-CSF for Advanced Malignancies Expressing the HER-2/neu Antigen (Summary Last Modified 12/98)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Closed
18 and over
Other
GUMC-34594
NCI-V96-0970
Last Modified:
6/25/2007
2.
Phase IA/IB Study of the Bispecific Antibody 520C9xH22 (MDX-H210) plus Interferon gamma in Metastatic Adenocarcinomas Expressing the HER2/neu Antigen
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
18 and over
Pharmaceutical / Industry
MDX-DMS-9318
DMS-9318, NCI-V94-0450
Last Modified:
6/25/2007
3.
Phase I Study of Bispecific Antibody 520C9xH22 for Advanced Malignancies Expressing the HER-2/neu Antigen
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
over 18
NCI, Pharmaceutical / Industry
NCI-95-C-0023L
MDX-NCI-95-C-0023L, NCI-MB-360
Last Modified:
6/1/1996
4.
Phase I Study of the Bispecific Antibody 520C9xH22 for Metastatic Prostate Cancer Expressing the HER2/neu Antigen (Summary Last Modified 06/96)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
over 18
Other
DMS-9403
NCI-V95-0626
Last Modified:
6/25/2007
5.
Phase I Study of Bispecific Antibody 520C9xH22 with G-CSF for Relapsed/Refractory Metastatic Cancer that Overexpresses HER2/neu
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
18 and over
Pharmaceutical / Industry
MDX-1B-95-2
LAC-USC-1B952, NCI-V95-0658
Last Modified:
4/1/1994
6.
Phase Ia/b Study of the Bispecific Antibody 520C9x22 Given Intravenously or Intraperitoneally in Patients with Advanced Breast or Ovarian Carcinoma (Summary Last Modified 04/94)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
over 18
DMS-9221
NCI-V93-0220
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute